Additionally, the 36-month beta value for GOSS is 1.88. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for GOSS is 182.66M and currently, short sellers hold a 6.07% ratio of that float. The average trading volume of GOSS on June 26, 2025 was 1.54M shares.
GOSS) stock’s latest price update
Gossamer Bio Inc (NASDAQ: GOSS)’s stock price has dropped by -1.45 in relation to previous closing price of 1.38. Nevertheless, the company has seen a gain of 9.68% in its stock price over the last five trading days. businesswire.com reported 2025-06-16 that SAN DIEGO–(BUSINESS WIRE)—- $GOSS–Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced enrollment completion for the ongoing, global registrational Phase 3 PROSERA Study evaluating seralutinib in Functional Class II and III PAH patients. Gossamer Bio and t.
GOSS’s Market Performance
Gossamer Bio Inc (GOSS) has experienced a 9.68% rise in stock performance for the past week, with a 13.33% rise in the past month, and a 6.25% rise in the past quarter. The volatility ratio for the week is 6.87%, and the volatility levels for the past 30 days are at 4.17% for GOSS. The simple moving average for the past 20 days is 7.23% for GOSS’s stock, with a 33.28% simple moving average for the past 200 days.
Analysts’ Opinion of GOSS
Many brokerage firms have already submitted their reports for GOSS stocks, with Oppenheimer repeating the rating for GOSS by listing it as a “Outperform.” The predicted price for GOSS in the upcoming period, according to Oppenheimer is $9 based on the research report published on June 25, 2024 of the previous year 2024.
Wedbush, on the other hand, stated in their research note that they expect to see GOSS reach a price target of $4. The rating they have provided for GOSS stocks is “Outperform” according to the report published on April 05th, 2024.
UBS gave a rating of “Neutral” to GOSS, setting the target price at $1.25 in the report published on July 27th of the previous year.
GOSS Trading at 21.37% from the 50-Day Moving Average
After a stumble in the market that brought GOSS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.26% of loss for the given period.
Stock Fundamentals for GOSS
Current profitability levels for the company are sitting at:
- -0.44 for the present operating margin
- 1.0 for the gross margin
The net margin for Gossamer Bio Inc stands at -0.41. The total capital return value is set at -0.24. Equity return is now at value -500.57, with -18.98 for asset returns.
Based on Gossamer Bio Inc (GOSS), the company’s capital structure generated 1.03 points at debt to capital in total, while cash flow to debt ratio is standing at 0.05. The debt to equity ratio resting at -32.31. The interest coverage ratio of the stock is -4.92.
Currently, EBITDA for the company is -39.97 million with net debt to EBITDA at -4.84. When we switch over and look at the enterprise to sales, we see a ratio of 3.87. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.71.
Conclusion
In conclusion, Gossamer Bio Inc (GOSS) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
